AI Article Synopsis
- Hereditary cancer risk assessment (HCRA) evaluates the likelihood of genetic mutations linked to cancer and the associated risks based on personal and family medical history.
- It involves a team approach, including genetic counseling and testing, enabling individuals to make informed decisions about their health management options, like screening and treatment.
- Following high-risk patients with targeted screening and referring them to specialized centers ensures better management of hereditary cancer risks.
Article Abstract
Hereditary cancer risk assessment (HCRA) is a multidisciplinary process of estimating probabilities of germline mutations in cancer susceptibility genes and assessing empiric risks of cancer, based on personal and family history. It includes genetic counseling, testing and management of at-risk individuals so that they can make well-informed choices about cancer surveillance, surgical treatment and chemopreventive measures, including biomolecular cancer therapies. Providing patients and family members with an appropriate HCRA will contribute to a better process of making decisions about their personal and family risks of cancer. Following individuals at high risk through screening protocols, reassuring those at low risk, and referring those at increased risk of hereditary cancer to a cancer genetics center may be the best suitable approach of HCRA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231335 | PMC |
| http://dx.doi.org/10.1186/1897-4287-11-16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An evolutionary perspective for the exposome.
Exposome
February 2024
MRC Centre for Environment and Health, School of Public Health, Imperial College, London, UK.
The exposome was proposed following the realization that most human diseases have an environmental rather than a genetic (hereditary) origin. Non-communicable diseases are, in fact, the consequence of multiple exposures that activate a sequence of stages in a multistage process that already starts in early life. This attracted attention to both the multiplicity (in fact, potentially the totality) of exposures humans are exposed to since conception and to the life-long perspective of disease causation.
View Article and Find Full Text PDFLate Diagnosis of Familial Adenomatous Polyposis After Acute Lower Gastrointestinal Bleeding: A Case Report.
Cureus
December 2024
Gastrointestinal Bleeding Center, Cleriston Andrade General Hospital, Feira de Santana, BRA.
Familial adenomatous polyposis (FAP) is an autosomal dominant hereditary disease characterized by the progressive development of multiple adenomatous polyps along the colon. The majority of individuals develop colorectal cancer by the age of 40 within the evolutionary course of the disease. For this reason, screening family members is essential to enable identification, surveillance, and appropriate intervention.
View Article and Find Full Text PDFA Rare Case Report of Extra-adrenal Pheochromocytoma Masquerading as a Pancreatic Head Malignancy.
Cureus
December 2024
Internal Medicine, University of Florida College of Medicine, Pensacola, USA.
Extra-adrenal pheochromocytomas are rare neuroendocrine tumors originating outside the adrenal glands and can pose significant diagnostic challenges due to their variable presentations. This report highlights a case of an extra-adrenal pheochromocytoma masquerading as a pancreatic head malignancy. We underscore the importance of considering extra-adrenal pheochromocytoma in the differential diagnosis of pancreatic masses, particularly when biochemical or clinical features suggest catecholamine excess.
View Article and Find Full Text PDFGenetic testing to identify hereditary predispositions to haematological malignancy is critical prior to allogenic haematopoietic cell transplant.
Br J Haematol
January 2025
Oncogenesis and Development Section, Translational and Functional Genomics Branch (TFGB), National Human Genome Research Institute (NHGRI), Bethesda, Maryland, USA.
Label-free proteomic analysis of Duchenne and Becker muscular dystrophy showed decreased sarcomere proteins and increased ubiquitination-related proteins.
Sci Rep
January 2025
Graduate Course in Medicine (Pathological Anatomy), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Muscular dystrophies (MD) are a group of hereditary diseases marked by progressive muscle loss, leading to weakness and degeneration of skeletal muscles. These conditions often result from structural defects in the Dystrophin-Glycoprotein Complex (DGC), as seen in Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Since MDs currently have no cure, research has focused on identifying potential therapeutic targets to improve patients' quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!